crescent biopharma inc - CBIO
CBIO
Close Chg Chg %
20.88 -0.42 -2.01%
Pre-Market
20.46
-0.42 (2.01%)
Volume: 647.21K
Last Updated:
Sep 8, 2026, 4:00 PM EDT
Company Overview: crescent biopharma inc - CBIO
CBIO Key Data
| Open $20.58 | Day Range 19.91 - 21.17 |
| 52 Week Range 8.72 - 27.41 | Market Cap $775.56M |
| Shares Outstanding 37.14M | Public Float 30.86M |
| Beta 1.23 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$7.65 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 255.16K |
CBIO Performance
| 1 Week | -2.01% | ||
| 1 Month | 21.50% | ||
| 3 Months | 14.17% | ||
| 1 Year | 63.81% | ||
| 5 Years | -90.91% |
CBIO Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
8
Full Ratings ➔
About crescent biopharma inc - CBIO
Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.
CBIO At a Glance
Crescent Biopharma, Inc.
300 Fifth Avenue
Waltham, Massachusetts 02451
| Phone | 1-617-430-5595 | Revenue | 10.84M | |
| Industry | Biotechnology | Net Income | -153,942,000.00 | |
| Sector | Health Technology | Employees | 44 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
CBIO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 11.389 |
| Price to Book Ratio | 1.642 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.551 |
| Enterprise Value to Sales | -7.75 |
| Total Debt to Enterprise Value | -0.02 |
CBIO Efficiency
| Revenue/Employee | 246,454.545 |
| Income Per Employee | -3,498,681.818 |
| Receivables Turnover | 0.602 |
| Total Asset Turnover | 0.086 |
CBIO Liquidity
| Current Ratio | 6.561 |
| Quick Ratio | 6.561 |
| Cash Ratio | 5.91 |
CBIO Profitability
| Gross Margin | 99.225 |
| Operating Margin | -1,407.525 |
| Pretax Margin | -1,401.162 |
| Net Margin | -1,419.605 |
| Return on Assets | -122.475 |
| Return on Equity | -147.79 |
| Return on Total Capital | -75.22 |
| Return on Invested Capital | -146.937 |
CBIO Capital Structure
| Total Debt to Total Equity | 0.81 |
| Total Debt to Total Capital | 0.803 |
| Total Debt to Total Assets | 0.684 |
| Long-Term Debt to Equity | 0.608 |
| Long-Term Debt to Total Capital | 0.591 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Crescent Biopharma Inc - CBIO
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | 75.00K | 10.00K | 10.84M | |
Sales Growth
| - | -93.53% | -86.67% | -100.00% | |
Cost of Goods Sold (COGS) incl D&A
| 1.03M | 153.30K | 35.17K | 84.00K | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 1.03M | 153.30K | 35.17K | 84.00K | |
Depreciation
| 1.03M | 153.30K | 35.17K | 84.00K | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| +1.83% | -85.15% | -77.06% | +138.81% | |
Gross Income
| (957.16K) | (143.30K) | (35.17K) | 10.76M | |
Gross Income Growth
| -755.01% | +85.03% | +75.45% | +30,690.78% | |
Gross Profit Margin
| - | -1,276.21% | -1,433.01% | +99.23% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 46.45M | 39.13M | 32.47M | 163.39M | |
Research & Development
| 28.39M | 20.07M | 14.26M | 138.09M | |
Other SG&A
| 18.06M | 19.06M | 18.21M | 25.31M | |
SGA Growth
| -26.96% | -15.75% | -17.01% | +403.15% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | 7.53M | - |
EBIT after Unusual Expense
| (47.40M) | (39.28M) | (40.04M) | (152.63M) | |
Non Operating Income/Expense
| 714.52K | 2.38M | 2.16M | 2.88M | |
Non-Operating Interest Income
| 714.52K | 2.38M | 935.27K | 2.88M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | 2.19M | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | 2.19M | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (46.69M) | (36.90M) | (37.88M) | (151.94M) | |
Pretax Income Growth
| +26.39% | +20.97% | -2.66% | -301.12% | |
Pretax Margin
| - | -62,251.74% | -368,994.20% | -1,401.16% | |
Income Tax
| - | - | - | 2.00M | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | 2.00M | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (46.69M) | (36.90M) | (37.88M) | (153.94M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (46.69M) | (36.90M) | (37.88M) | (153.94M) | |
Net Income Growth
| +26.39% | +20.97% | -2.66% | -306.40% | |
Net Margin Growth
| - | -62,251.74% | -368,994.20% | -1,419.61% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (46.69M) | (36.90M) | (37.88M) | (153.94M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (46.69M) | (36.90M) | (37.88M) | (153.94M) | |
EPS (Basic)
| -88.878 | -58.254 | -58.748 | -14.7827 | |
EPS (Basic) Growth
| +27.90% | +34.46% | -0.85% | +74.84% | |
Basic Shares Outstanding
| 525.31K | 633.42K | 644.77K | 10.41M | |
EPS (Diluted)
| -88.878 | -58.254 | -58.748 | -14.7827 | |
EPS (Diluted) Growth
| +27.90% | +34.46% | -0.85% | +74.84% | |
Diluted Shares Outstanding
| 525.31K | 633.42K | 644.77K | 10.41M | |
EBITDA
| (46.37M) | (39.12M) | (32.47M) | (152.55M) | |
EBITDA Growth
| +25.73% | +15.63% | +16.99% | -369.76% | |
EBITDA Margin
| - | -61,828.21% | -391,219.90% | -1,406.75% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 29.167 | |
| Number of Ratings | 8 | Current Quarters Estimate | -0.674 | |
| FY Report Date | 09 / 2026 | Current Year's Estimate | -2.766 | |
| Last Quarter’s Earnings | -0.74 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -12.81 | Next Fiscal Year Estimate | -2.911 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 7 | 7 | 7 | 7 |
| Mean Estimate | -0.67 | -0.70 | -2.77 | -2.91 |
| High Estimates | -0.53 | -0.62 | -2.35 | -1.98 |
| Low Estimate | -0.85 | -0.86 | -3.30 | -4.60 |
| Coefficient of Variance | -14.46 | -12.21 | -12.05 | -31.92 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 7 | 7 | 7 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 1 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Crescent Biopharma Inc - CBIO
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Crescent Biopharma Inc - CBIO
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jun 24, 2026 | Ryan Lynch See Remarks | 13,871 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $17.99 per share | 249,539.29 |
| Jun 24, 2026 | Joshua T. Brumm Chief Executive Officer; Director | 281,212 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $17.99 per share | 5,059,003.88 |
| Jun 24, 2026 | Richard William Scalzo Chief Financial Officer | 20,298 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $17.99 per share | 365,161.02 |
| Jun 24, 2026 | Jonathan McNeill President and COO | 139,158 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $17.99 per share | 2,503,452.42 |
| Jun 24, 2026 | Jan Pinkas Chief Scientific Officer | 22,239 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $17.99 per share | 400,079.61 |
| Jun 24, 2026 | Ellie Im Chief Medical Officer | 22,069 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $17.99 per share | 397,021.31 |
| Jun 24, 2026 | Barbara Bispham Hale See Remarks | 19,330 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $17.99 per share | 347,746.70 |
| Jun 5, 2026 | David Charles Lubner Director | 11,050 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 5, 2026 | Jonathan Violin Director | 11,050 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 5, 2026 | Alexandra Balcom Director | 11,050 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |